About Rahul Aggarwal
Dr. Rahul Aggarwal is a Medical Oncologist within the Division of Hematology/Oncology at the University of San Francisco, California (UCSF) Helen Diller Family Comprehensive Cancer Center. Dr. Aggarwal also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men with prostate cancer who are receiving androgen deprivation therapy, also known as hormone therapy. In addition, as a member of the Developmental Therapeutics Genitourinary Cancer Program, Dr. Aggarwal enrolls patients with advanced solid tumor malignancies into early phase clinical trials of novel targeted treatments. His research is focused on developing novel hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer.
Dr. Aggarwal received his MD from Northwestern University Feinberg in 2006. Dr. Aggarwal was also the recipient of the 2015 John Paulson PCF Young Investigator Award, where he designed and initiated a study to determine whether the combination of docetaxel chemotherapy plus ribociclib would show promise as a new method of treatment for men with advanced hormone resistant prostate cancer.